MA55760A - Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde - Google Patents

Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde

Info

Publication number
MA55760A
MA55760A MA055760A MA55760A MA55760A MA 55760 A MA55760 A MA 55760A MA 055760 A MA055760 A MA 055760A MA 55760 A MA55760 A MA 55760A MA 55760 A MA55760 A MA 55760A
Authority
MA
Morocco
Prior art keywords
diagnosing
methods
rheumatoid arthritis
treating rheumatoid
treating
Prior art date
Application number
MA055760A
Other languages
English (en)
Inventor
Anita Boyapati
Jérôme Msihid
Moshe E Zilberstein
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Moshe E Zilberstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology, Moshe E Zilberstein filed Critical Regeneron Pharma
Publication of MA55760A publication Critical patent/MA55760A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
MA055760A 2019-04-24 2020-04-24 Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde MA55760A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837793P 2019-04-24 2019-04-24
EP20305193 2020-02-27

Publications (1)

Publication Number Publication Date
MA55760A true MA55760A (fr) 2022-03-02

Family

ID=70736802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055760A MA55760A (fr) 2019-04-24 2020-04-24 Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde

Country Status (15)

Country Link
US (1) US12440561B2 (fr)
EP (1) EP3959240A1 (fr)
JP (1) JP2022545312A (fr)
KR (1) KR20220088829A (fr)
CN (1) CN114651010A (fr)
AU (1) AU2020261431A1 (fr)
BR (1) BR112021021077A2 (fr)
CA (1) CA3137909A1 (fr)
CO (1) CO2021015660A2 (fr)
IL (1) IL287263A (fr)
MA (1) MA55760A (fr)
MX (1) MX2021012969A (fr)
SG (1) SG11202111742QA (fr)
TW (1) TW202106712A (fr)
WO (1) WO2020219960A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱
KR102818005B1 (ko) 2025-03-04 2025-06-11 김환배 전자렌지용 저당밥솥

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432103A (en) 1977-08-16 1979-03-09 Nissan Motor Co Ltd Preparing apparatus for composite molten metal containing solid particles in dispersed state
JPS5870649A (ja) 1981-10-22 1983-04-27 Toyota Motor Corp ダイバ−シテイ受信システム
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
EP0409607B1 (fr) 1989-07-20 1996-10-30 Tadamitsu Kishimoto Anticorps contre le récepteur de l'interleukin-6
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
EP1097945B1 (fr) 1991-03-18 2007-07-04 New York University Anticorps monoclonaux et chimèriques dirigés spécifiquement contre le facteur humain de nécrose tumorale
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
EP0672144A1 (fr) 1992-10-20 1995-09-20 Chiron Corporation Antagonistes du recepteur d'interleukine 6
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (fr) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System Anticorps monoclonaux diriges contre le recepteur de l'il-6 humaine
EP0783893B1 (fr) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif
WO1996012503A1 (fr) 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remede contre des maladies provoquees par la production d'il-6
JP4079461B2 (ja) 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
CA2211578C (fr) 1995-02-13 2010-09-21 Chugai Seiyaku Kabushiki Kaisha Agent inhibitant la proteolyse des proteines musculaires contenant un anticorps dirige contre le recepteur de l'il-6
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6046223A (en) 1996-02-26 2000-04-04 Advanced Research & Technology Institute Treatment of macular edema
DE69735888T2 (de) 1996-06-27 2006-11-02 Chugai Seiyaku K.K. Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
HU225539B1 (en) 1998-03-17 2007-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
WO2000010607A1 (fr) 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Produits preventifs ou therapeutiques de la pancreatite contenant des antagonistes de il-6 comme substance active
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
AU2002210952B2 (en) 2000-10-25 2007-01-11 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
WO2003009817A2 (fr) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
ES2436206T3 (es) 2001-11-14 2013-12-27 Janssen Biotech, Inc. Anticuerpos anti il-6, composiciones, métodos y usos
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
EP2062916A3 (fr) 2003-04-09 2009-08-19 Genentech, Inc. Traitement d'une maladie autoimmune chez un patient dont la réponse à un inhibiteur TNF-Alpha n'est pas adéquate
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (fr) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Utilisation d'un compose pour reduire l'efficacite biologique de l'il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005080429A2 (fr) 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methodes de traitement de l'osteoarthrose avec des antagonistes de l'interleukine-6
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
EP2399936A3 (fr) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anticorps anti-CD154
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
WO2006046661A1 (fr) 2004-10-28 2006-05-04 Osaka University Agent inhibiteur de l’interleucine-6
EP1828250A2 (fr) 2004-12-16 2007-09-05 Genentech, Inc. Procedes de traitement de troubles auto-immuns
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
JP2009516692A (ja) 2005-11-22 2009-04-23 ワイス 免疫グロブリン融合タンパク質製剤
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
US20070143168A1 (en) 2005-12-19 2007-06-21 Lucent Technologies Inc. Meeting scheduling service
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EP2029163A4 (fr) 2006-06-14 2010-08-11 Imclone Llc Formulations lyophilisees d'anticorps anti-egfr
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008049897A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de protéines
EP2666787B1 (fr) 2007-05-31 2022-02-09 Genmab A/S ANTICORPS IgG4 STABLES
WO2009041621A1 (fr) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps du récepteur anti-il-6
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
WO2009109584A1 (fr) 2008-03-07 2009-09-11 Ferring International Center S. A. Anticorps qui ne se lie qu'au complexe il6-sil6r
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
AU2009246430B2 (en) 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI440470B (zh) 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
CN102470103B (zh) 2009-07-07 2016-09-07 贝林格尔.英格海姆国际有限公司 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
NZ603191A (en) 2010-05-07 2015-02-27 Xoma Technology Ltd Methods for the treatment of il-1b related conditions
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9261526B2 (en) 2010-08-26 2016-02-16 Blast Motion Inc. Fitting system for sporting equipment
EP2638067A2 (fr) 2010-11-08 2013-09-18 Genentech, Inc. Anticorps anti-récepteur de l'il-6 administré par voie sous-cutanée
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
CA2746171C (fr) 2011-07-13 2018-11-06 William Jani Bouchon de fracturation recuperable
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
CN103947096B (zh) 2011-10-21 2016-09-21 Abb研究有限公司 用于检测ac/dc转换器中失效整流器的方法和系统
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
HK1211599A1 (en) 2012-11-08 2016-05-27 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
SG10201913330SA (en) 2013-09-11 2020-03-30 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
US11046975B2 (en) 2013-10-07 2021-06-29 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
WO2015077582A1 (fr) 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions pour le traitement de la polyarthrite rhumatoïde et méthodes d'utilisation desdites compositions
ES2799439T3 (es) 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
PT3193934T (pt) * 2014-09-16 2021-10-19 Regeneron Pharma Composições para melhoria da qualidade de vida relacionada com a saúde de pacientes com artrite reumatoide
TW201723174A (zh) 2015-09-03 2017-07-01 持田製藥股份有限公司 重組蛋白質的製造方法
EP3371224A1 (fr) 2015-11-03 2018-09-12 Sanofi Biotechnology Compositions comprenant des anticorps il6r pour le traitement de l'uvéite et l'oedème maculaire et leurs procédés d'utilisation
WO2017106312A1 (fr) 2015-12-18 2017-06-22 Drexel University Méthodes de modulation de niveaux d'il-6 et de pd-l1
TWI819435B (zh) 2016-03-07 2023-10-21 法商賽諾菲生物技術公司 用於治療類風濕性關節炎之組成物及方法
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
WO2018007442A1 (fr) * 2016-07-06 2018-01-11 Ablynx N.V. Traitement de maladies associées à l'il-6r
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
CH715771A2 (de) 2019-01-23 2020-07-31 Pedretti Mauro Verfahren und Vorrichtung zum Speichern von Energie.
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
CA3143261A1 (fr) 2019-06-12 2020-12-17 Sanofi Biotechnology Dosage modifie de tocilizumab sous-cutane pour la polyarthrite rhumatoide
US12135885B2 (en) 2020-01-31 2024-11-05 Hewlett Packard Enterprise Development Lp Virtual storage policies for virtual persistent volumes
BR112022024020A2 (pt) 2020-05-26 2023-04-04 Feist Eugen Composições compreendendo um anticorpo contra receptor de interleucina-6 para tratamento de artrite reumatoide e métodos de uso das mesmas
WO2021240436A1 (fr) 2020-05-29 2021-12-02 Sanofi Biotechnology Compositions et méthodes pour le traitement d'une douleur non-inflammatoire chez des sujets atteints de polyarthrite rhumatoïde

Also Published As

Publication number Publication date
US20200405851A1 (en) 2020-12-31
CN114651010A (zh) 2022-06-21
TW202106712A (zh) 2021-02-16
WO2020219960A1 (fr) 2020-10-29
EP3959240A1 (fr) 2022-03-02
CA3137909A1 (fr) 2020-10-29
AU2020261431A1 (en) 2021-12-09
KR20220088829A (ko) 2022-06-28
JP2022545312A (ja) 2022-10-27
CO2021015660A2 (es) 2022-02-17
SG11202111742QA (en) 2021-11-29
MX2021012969A (es) 2022-06-09
BR112021021077A2 (pt) 2021-12-14
US12440561B2 (en) 2025-10-14
IL287263A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MA55760A (fr) Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
EP3814860A4 (fr) Analyse d'apprentissage machine de diagrammes de tuyauterie et d'instrumentation
EP3796666A4 (fr) Procédé et appareil de traitement de signal vidéo
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
EP3723416A4 (fr) Procédé et appareil de traitement de session
EP3880854A4 (fr) Procédé et appareil de traitement de magnétite
EP3873197A4 (fr) Systèmes et procédés de traitement de plantes automatisés
EP3535567A4 (fr) Appareil d'inspection de solide et procédé d'utilisation
EP3844606C0 (fr) Appareil audio et procédé de traitement audio
EP4040284A4 (fr) Procédé de traitement de son et appareil associé
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA52251A (fr) Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
EP3880853A4 (fr) Procédé et appareil de traitement de magnétite
EP3880855A4 (fr) Procédé et appareil pour le traitement de la magnétite
EP3776448A4 (fr) Système et procédé de traitement de passagers
EP3893523A4 (fr) Procédé et appareil de traitement de signal audio
EP3806710A4 (fr) Procédé, système et appareil d'évaluation diagnostique et de dépistage de dysfonctionnements binoculaires
EP3523639C0 (fr) Réactifs de détection et agencements d'électrodes pour éléments de test de diagnostic multi-analytes, ainsi que leurs procédés d'utilisation
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP4182943A4 (fr) Systèmes et procédés de traitement ultrasonore de poumon
EP4061264A4 (fr) Systèmes et procédés de traitement de graisse viscérale
EP3801510A4 (fr) Procédés de traitement de dystrophies musculaires
EP3979416A4 (fr) Procédé et appareil de détection d'anomalie
EP3875206A4 (fr) Système de traitement et procédé de traitement
EP3956848A4 (fr) Systèmes et procédés de traitement en temps réel